Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
mice, accumulation of GMP and MDSC was prevented, whereas systemic output of effector myeloid cells was increased. Myeloid cell-specific PD-1 ablation induced an increase of T effector memory cells with improved functionality and mediated antitumor protection despite preserved PD-1 expression in T cells. In PD-1-deficient myeloid progenitors, growth factors driving emergency myelopoiesis induced increased metabolic intermediates of glycolysis, pentose phosphate pathway, and TCA cycle but, most prominently, elevated cholesterol. Because cholesterol is required for differentiation of inflammatory macrophages and DC and promotes antigen-presenting function, our findings indicate that metabolic reprogramming of emergency myelopoiesis and differentiation of effector myeloid cells might be a key mechanism of antitumor immunity mediated by PD-1 blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PD-1 can be expressed on some myeloid cells as well, and changes in the myeloid compartment could lead to an influx of inflammatory cells into various, distant tissues/organs and inciting organ damage”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Strauss et al., 2020
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247 · cited 2×
“However, similar to its role in infections, PD-1 expression inversely correlates with M1 polarization and phagocytic potency of tumor-associated M (TAM) against tumor (7, 8).”
BackgroundActivation of a metabolic gene regulatory network downstream of mTOR complex 1
Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.022 · Cited by 2,020
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797 · cited 2×
“Myeloid-specific PD-1 ablation induces improved T cell functionality Previously, it was determined that monocyte/macrophage terminal differentiation is controlled by the combined actions of retinoid receptors and the nuclear receptor peroxisome proliferator–activated receptor (PPAR), which is regulated by cholester…”
BackgroundSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Cited by
Items 401–459 of 459
Phadke, M. S., Chen, Z., Li, J., Mohamed, E. T., Davies, M. A., Smalley, I., Duckett, D. R., Palve, V. C., Czerniecki, B. J., Forsyth, P. A., et al. (2023) · doi:10.1158/2326-6066.c.6550279
Wang, G., Chow, R. D.-W., Zhu, L., Bai, Z., Ye, L., Zhang, F., Renauer, P. A., Dong, M. B., Dai, X., Zhang, X., et al. (2023) · doi:10.1158/2159-8290.c.6547756.v1
Singh, L., Muise, E. S., Bhattacharya, A., Grein, J., Javaid, S., Stivers, P., Zhang, J., Qu, Y., Joyce-Shaikh, B., Loboda, A. P., et al. (2023) · doi:10.1158/1541-7786.c.6545345.v1
Haas, M., Kagey, M. H., Heath, H., Schuerpf, F., Rottman, J. B., & Newman, W. (2023) · doi:10.1158/1541-7786.c.6545285.v1
Dynamique des interactions entre cellules immunes lors de régressions tumorales
Guérin, M. V. (2020) · theses.fr (ABES) · doi:10.70675/14fd93bfze334z4242z86f9z1bb7b8755bf0
Semitekolou, M., Paschalidis, N., Tartaro, D. L., Tsitsopoulou, A., Stamou, P., Mavroudis, A., Markaki, E., Varveri, A., Morianos, I., Lavigne, M. D., et al. (2024) · medRxiv · doi:10.1101/2024.08.27.24312529
“Since our data suggest that PD-L1-expressing CD8 + T cells could predict responses to aPD1 immunotherapy we sought to validate these results through flow cytometry analysis.”
BackgroundInfluentialVerginis, P., Semitekolou, M., Paschalidis, N., Tartaro, D. L., Tsitsopoulou, A., Stamou, P., Mavroudis, A., Markaki, E., Varveri, A., Morianos, I., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4874581/v1
Caractérisation des effets de PD-1 sur la synapse immunologique
Paillon, N. (2023) · theses.fr (ABES) · doi:10.70675/aa4d4ce9z04a6z4d5cz89a8zcb69e3c44901
Kirane, A., Lee, D., Sharma, S., Safrygina, E., Applebee, C. J., Serasanambati, M., Singh, P., Chadokiya, J., Wagner, E., Meerlev, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.30.667666 · Cited by 1
Reynaud, E., Belherazem, S., Sener, Ö. C., Hofmann, S., Acari, A., Lodha, P., Hemanna, S., Coianiz, N., Ast, V., Tugues, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.22.671842
Chronic inflammation induced immunosuppression
Greten, F. R., & Pesic, M. H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00048-5
Molecular determinants of brain-resident CD8 + T cell formation and functionPreprint
Elmzzahi, T., Su, C.-H., Shakiba, M. H., Hamada, D., Malko, D., Köhne, M., Frolov, A., Mason, T., Scholz, R., Li, Y., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.26.672425
Self-citationCheckpoint Inhibitors and Combination Strategies in Colorectal Cancer: an Overview
Poznyak, A. V., Shakhpazyan, N. K., Utkina, A. S., Korchagina, E. R., Maltseva, O. N., & Orekhov, A. N. (2025) · Journal of Carcinogenesis · doi:10.64149/j.carcinog.24.8s.91-121
Trécesson, S. D. C., East, P., Pillsbury, C. E., dos Santos, M. S., Cha, H., Colliver, E., Gilmore, T., Rana, S., Moore, C., Lighterness, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.25.690426
Tsuneyoshi, N., Hosoya, T., Takeno, Y., Saitoh, K., Murai, H., Amimoto, N., Tatsumi, R., Watanabe, S., Hasegawa, Y., Kikkawa, E. F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26741663
Indino, S. (2023) · Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) · doi:10.13130/indino-serena-lucia_phd2023-01-27
Sun, Q., Xiao, L., Cui, Z., Yang, Y., Ma, J., Huang, Z., Zhang, J., & Chen, J. (2022) · Figshare · doi:10.6084/m9.figshare.20208254
Sun, Q., Xiao, L., Cui, Z., Yang, Y., Ma, J., Huang, Z., Zhang, J., & Chen, J. (2022) · Figshare · doi:10.6084/m9.figshare.20208257
Shevela, E. Y., Sakhno, L. V., Tikhonova, M. A., Викторовна, Т. Т., Morenkova, A. Y., Александровна, Ч. О., Ilina, N. A., Сергеевна, Ш. Н., Kurochkina, Y. D., Fedorova, A. V., et al. (2025) · Medical Immunology (Russia) · doi:10.15789/1563-0625-cai-3260
Additional file 1 of KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner
Laurent, P.-A., Milić, M., Quevrin, C., Meziani, L., Liu, W., Morel, D., Signolle, N., Clémenson, C., Lévy, A., Mondini, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24472444
Makrofagit syöpäkasvaimen mikroympäristössä
Kilpinen, K. (2025) · UTUPub (University of Turku)
Laaker, C. J., Hsu, M., Madrid, A., Port, J. M., Vrba, S. M., Herbáth, M., Baenen, C. M., Kumar, M., Priyathilaka, T. T., Sándor, M., et al. (2026) · eLife · doi:10.7554/elife.110460.3
Vidal, M. S., Kammala, A. K., Tatiparthy, M., Lintao, R. C. V., Cherukuri, R., Tantengco, O. A. G., Buffington, S. A., Radnaa, E., Richardson, L. S., & Menon, R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.15.699706
Laaker, C. J., Hsu, M., Madrid, A., Port, J. M., Vrba, S. M., Herbáth, M., Baenen, C. M., Kumar, M., Priyathilaka, T. T., Sándor, M., et al. (2026) · eLife · doi:10.7554/elife.110460.1
Yamaguchi, A., Suzuki, H., Takasuga, S., Tatematsu, M., Fuchimukai, A., Endo, T., Kaya, H., Morishita, A., Seki, S., Imai, K., et al. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2639723
Plying potency assays for immunotherapy of solid tumors
Burns, J. S., Gjeta, R., Lesný, P., & Vives, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1770222
“Complete PD-1 silencing (as opposed to transient antibody blockade) impairs CAR-T proliferation and prevents optimal effector-to-memory differentiation (59), while myeloid-speci fi c but not T-cell-speci fi c PD-1 ablation prevents immunosuppression in certain contexts (60).”
Growth and Mechanics of Cellular Structures : Continuous Models for Tissue Growth
Ackermann, J. (2022) · theses.fr (ABES) · doi:10.70675/775fa1e9z559cz46b4z8c0cz359a6b956498 · Cited by 2
Investigating the tumor-induced modifications of hematopoiesis during breast cancer
Gerber-Ferder, Y. (2022) · theses.fr (ABES) · doi:10.70675/90368efbz219dz41adz90b3z2fcc7e359988
Ruggiu, M. (2023) · theses.fr (ABES) · doi:10.70675/de84e089z4e46z475dz8d12z25950ab6f427
Efficacy and synergy of low-dose radiotherapy combined with anti-PD-L1 based immunotherapy
Laurent, P.-A. (2023) · theses.fr (ABES) · doi:10.70675/e7695737z26a3z4747zafafzb19e3e74372b
Stephan, P. (2023) · theses.fr (ABES) · doi:10.70675/52f6875dz170az448bz96acz3a4fd721bdcd
Yan, R., Zhang, K., Chen, J., Pan, Y., & Wang, H. (2026) · World Journal of Surgical Oncology · doi:10.1186/s12957-026-04305-7
Impact des thérapies anti-cancéreuses sur les macrophages associés aux tumeurs
Weber-Delacroix, E. (2024) · theses.fr (ABES) · doi:10.70675/b92dc645ze621z4e9fz897ez5f892a948cc9
Аистова, Л. Г., Fedorova, A. O., Bondarchuk, E. V., Анатольевна, Г. Е., & Геннадьевич, В. А. (2026) · Scientific Notes Kazan Bauman State Academy of Veterinary Medicine · doi:10.31588/2413_4201_1883_1_265_6
Laaker, C. J., Hsu, M., Madrid, A., Port, J. M., Vrba, S. M., Herbáth, M., Baenen, C. M., Kumar, M., Priyathilaka, T. T., Sándor, M., et al. (2026) · eLife · doi:10.7554/elife.110460.2
Laaker, C. J., Hsu, M., Madrid, A., Port, J. M., Vrba, S. M., Herbáth, M., Baenen, C. M., Kumar, M., Priyathilaka, T. T., Sándor, M., et al. (2026) · eLife · doi:10.7554/elife.110460.2.sa0
Celebrating a decade of progress at Science Immunology
Scanlon, S. T. (2026) · Science Immunology · doi:10.1126/sciimmunol.aej2535
Chandra, J., Wang, H., Hossain, T., Tillett, B. J., Berman, C., Nissen, M. D., Joseph, S. R., Simpson, F., Walpole, E. T., McCaffrey, E., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10134278/v1
Alimohammadi, M., Mirnejad, A. M., Farahani, N., Hedayati, N., & Hushmandi, K. (2026) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-026-06566-x
“When PD-1 was removed or blocked specifically in macrophages, in both mouse tumor models and CLL patient monocytes, anti-tumor immune responses improved greatly (Gordon et al. 2017; Qorraj et al. 2017; Strauss, et al. 2020).”
Wu, J., Zhou, D., Jiang, K., Li, Z., Ouyang, J., Feng, L., Liu, Z., & Luo, D. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118338
B7-H3 (CD276) regulates myeloid-derived suppressor cell differentiation in pulmonary fibrosis
Santos, F. G. D. L., Rosek, A., Ando, A., Phan, S. H., Mahadevan, N. R., & Liu, T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1903767
Next-generation macrophage engineering in cancer therapy: From TAM reprogramming to CAR-macrophages
Nilova, O., & Zajakina, A. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103060
Lv, K., He, Z., Chen, Q., Shi, Y., Wei, L., Yang, S., Li, D., Tang, S., Li, K., Wang, C., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08789-5
The Five-Decade Journey of Small Cell Lung Cancer
Chen, R., Xue, C., Zhong, Y., Huang, Q., Fan, Q., Li, Y., Wu, J., Dong, S., Li, X., Xiao, T., et al. (2026) · 癌症:英文版 · doi:10.34133/cancomm.0052
Wang, M., Pan, M., & Hung, Y. (2026) · In Vivo · doi:10.21873/invivo.14427
Zhang, Y., Yu, X., Yao, Y., Cho, W. C., & Shang, A. (2026) · Cancer Bioscience · doi:10.1016/j.cbs.2026.100009
Leplina, O. Y., Tikhonova, M. A., Васильевич, Б. Е., Ращупкин, И. М., Викторовна, Т. Т., & Chernykh, E. R. (2026) · Immunologiya · doi:10.33029/0206-4952-2026-47-3-342-351
Therapeutic Cancer Vaccines: Classification, Mechanisms, Challenges and Future Perspectives
Gao, J., Sun, Y., Han, Z., Zhang, H., Sun, M., Liu, S., & Zhang, B. (2026) · Immunological Investigations · doi:10.1080/08820139.2026.2733761
Godin, S., Kingma, T. J., Pillai, A. A., Kholoki, O., & Kim, A. S. (2026) · Cancer Reports · doi:10.1002/cnr2.70675
“While this mechanism is key for antitumor immunity, it underscores the systemic metabolic and vascular trade-offs potentially inherent to PD-1 blockade [36].”
Wang, C., Zhang, L., Zhang, C., Li, G., & Zhou, R. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s616232
Integrating biology and mathematics to understand checkpoint immunotherapy
Sousa, R. S., Moshensky, A., Murat, C., Geels, S. N., Lowengrub, J. S., & Marangoni, F. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.09.004
Islam, M. R., Patel, J., Back, P. I., Modaresahmadi, S., Markiewski, M. M., Triplett, T., & La-Beck, N. M. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115428
Abbas, B., Abbas, A., Khan, I., & Nazeer, S. (2026) · Clinical Immunology · doi:10.1016/j.clim.2026.110782
Xue, J., Zhang, L., Ning, C., Zhang, K., Xun, Z., Chen, Z., Zheng, H., Li, C., Piao, M., Zhou, K., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1992385
Wu, B., Zhang, W., Shu, Y., Chen, X., Yang, K., & Hu, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-03077-6
Metadata
- Authors
- Strauss, L., Mahmoud, M. A. A., Weaver, J. D., Tijaro-Ovalle, N. M., Christofides, A., Wang, Q., Pal, R., Yuan, M., Asara, J., Patsoukis, N., & Boussiotis, V. A.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Boussiotis, Vassiliki A.
- ORCID
- Venue
- Science Immunology
- Published
- 2020-01-03
- Volume
- 5
- Issue
- 43
- ISSN
- 2470-9468 (ISSN-L)
- PMC
- PMC7183328
- OpenAlex
- W2997277554
- Cited by
- 437
- References
- 73
- Citations by year
- 2026: 30 · 2025: 51 · 2024: 67 · 2023: 83 · 2022: 70 · 2021: 77 · 2020: 59
- FWCI
- 26.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA183605, P01CA142106, R01CA212605)
- National Institute of Allergy and Infectious Diseases (R56AI098129)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R21AR073494)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-1, myeloid cells, antitumor immunity, myeloid-derived suppressor cells, good manufacturing practices, emergency myelopoiesis, myeloid progenitor cells, cholesterol metabolism, metabolic reprogramming, macrophage differentiation, dendritic cell differentiation, anti-PD-1 therapy, tumor immunology
- MeSH terms
- Animals, Cell Differentiation, Colonic Neoplasms, Female, Male, Melanoma, Mice, Inbred C57BL, Mice, Transgenic, Myeloid Cells, Cell Line, Tumor, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.